Literature DB >> 22552932

Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency.

Rianne A Ronden1, Alfons J H M Houben, Tom Teerlink, Jaap A Bakker, Jörgen Bierau, Coen D A Stehouwer, Peter W De Leeuw, Abraham A Kroon.   

Abstract

Plasma concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) increase already in the early stages of renal insufficiency. There is no agreement as to whether reduced renal plasma clearance (RPCL) contributes to this increase. Therefore, we investigated the relationship between estimated glomerular filtration rate (eGFR), RPCL, and plasma ADMA and SDMA in essential hypertensive patients with mild to moderate renal insufficiency. In 171 patients who underwent renal angiography, we drew blood samples from the aorta and both renal veins and measured mean renal blood flow (MRBF) using the (133)Xe washout technique. RPCL was calculated using arteriovenous concentration differences and MRBF. After correction for potential confounders, reduced eGFR was associated with higher plasma ADMA and SDMA [standardized regression coefficient (β) = -0.22 (95% confidence intervals: -0.41, -0.04) and β = -0.66 (95% confidence intervals: -0.83, -0.49), respectively]. However, eGFR was not independently associated with RPCL of ADMA. Moreover, reduced RPCL of ADMA was not associated with higher plasma ADMA. Contrary to ADMA, reduced eGFR was indeed associated with lower RPCL of SDMA [β = 0.21 (95% confidence intervals: 0.02, 0.40)]. In conclusion, our findings indicate that RPCL of ADMA is independent of renal function in hypertensive patients with mild to moderate renal insufficiency. Unlike the case for SDMA, reduced RPCL of ADMA is of minor importance for the increase in plasma ADMA in these patients, which indicates that increased plasma ADMA in this population is not a direct consequence of the kidneys failing as a plasma ADMA-regulating organ.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552932     DOI: 10.1152/ajprenal.00045.2012

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  12 in total

1.  Kt/Vurea and Nonurea Small Solute Levels in the Hemodialysis Study.

Authors:  Timothy W Meyer; Tammy L Sirich; Kara D Fong; Natalie S Plummer; Tariq Shafi; Seungyoung Hwang; Tanushree Banerjee; Yunnuo Zhu; Neil R Powe; Xin Hai; Thomas H Hostetter
Journal:  J Am Soc Nephrol       Date:  2016-03-29       Impact factor: 10.121

2.  Asymmetric dimethylarginine, erythropoietin resistance, and anemia in CKD.

Authors:  Tammy L Sirich; Glenn M Chertow
Journal:  Ann Transl Med       Date:  2019-07

3.  Evaluation of Renal Biomarkers, Including Symmetric Dimethylarginine, following Gentamicin-Induced Proximal Tubular Injury in the Rat.

Authors:  Diane M Hamlin; A Eric Schultze; Michael J Coyne; Donald J McCrann; Rebekah Mack; Corie Drake; Rachel E Murphy; Julie Cross; Marilyn Strong-Townsend; Maha Yerramilli; Mary K Leissinger
Journal:  Kidney360       Date:  2021-12-07

4.  Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy.

Authors:  Zoltan Nemeth; Attila Cziraki; Sandor Szabados; Bernadett Biri; Sandor Keki; Akos Koller
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

5.  Arginine dimethylation products in pediatric patients with chronic kidney disease.

Authors:  Akram E El-Sadek; Eman G Behery; Ahmed A Azab; Naglaa M Kamal; Mostafa A Salama; Waleed E Abdulghany; Enas A A Abdallah
Journal:  Ann Med Surg (Lond)       Date:  2016-06-02

Review 6.  Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies.

Authors:  Sabrina Schlesinger; Svenja R Sonntag; Wolfgang Lieb; Renke Maas
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

7.  Increased Symmetric Dimethylarginine Level Is Associated with Worse Hospital Outcomes through Altered Left Ventricular Ejection Fraction in Patients with Acute Myocardial Infarction.

Authors:  Julie Lorin; Jean-Claude Guilland; Karim Stamboul; Charles Guenancia; Yves Cottin; Luc Rochette; Catherine Vergely; Marianne Zeller
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

8.  Does cardiac resynchronization therapy restore peripheral circulatory homeostasis?

Authors:  Chukwudiebube N Ajaero; Cher-Rin Chong; Nathan E K Procter; Saifei Liu; Yuliy Y Chirkov; Tamila Heresztyn; Wai Ping Alicia Chan; Margaret A Arstall; Andrew D McGavigan; Michael P Frenneaux; John D Horowitz
Journal:  ESC Heart Fail       Date:  2017-10-13

Review 9.  Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update.

Authors:  Stefanos Roumeliotis; Francesca Mallamaci; Carmine Zoccali
Journal:  J Clin Med       Date:  2020-07-23       Impact factor: 4.241

10.  Incidence of all-cause and cardiovascular mortality predicted by symmetric dimethylarginine in the population-based study of health in pomerania.

Authors:  Edzard Schwedhelm; Henri Wallaschofski; Dorothee Atzler; Marcus Dörr; Matthias Nauck; Uwe Völker; Heyo K Kroemer; Henry Völzke; Rainer H Böger; Nele Friedrich
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.